Results 151 to 160 of about 3,445 (263)

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

Return of warm conditions in the southeastern Bering Sea: Physics to fluorescence. [PDF]

PLoS One, 2017
Stabeno PJ, Duffy-Anderson JT, Eisner LB, Farley EV, Heintz RA, Mordy CW.   +5 more
europepmc   +1 more source

Gene Editing for Haemophilia—The Next Frontier

Haemophilia, EarlyView.
ABSTRACT The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults.
Mirko Pinotti, Gregory A. Newby, Sundar Selvaraj, Steven W. Pipe   +3 more
wiley   +1 more source

Return of warm conditions in the southeastern Bering Sea: Phytoplankton - Fish. [PDF]

PLoS One, 2017
Duffy-Anderson JT, Stabeno PJ, Siddon EC, Andrews AG, Cooper DW, Eisner LB, Farley EV, Harpold CE, Heintz RA, Kimmel DG, Sewall FF, Spear AH, Yasumishii EC.   +12 more
europepmc   +1 more source

Relationship Between hsCRP, Glycaemic Control and Response to Sotagliflozin in Type 1 Diabetes: A Post Hoc Analysis of the inTandem3 Trial

Diabetes, Obesity and Metabolism, EarlyView.
Luxcia Kugathasan, Michael J. Davies, Manon Girard, Erik Moedt, Marcel H. A. Muskiet, David Z. I. Cherney   +5 more
wiley   +1 more source

Seventh Åland Island Meeting on von Willebrand Disease

Haemophilia, EarlyView.
ABSTRACT Introduction The seventh Åland Island Meeting on von Willebrand Disease (VWD) was held on the Åland archipelago in Finland, from 26 to 28 September 2024. Aim The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD.
Riitta Lassila, Ruben Bierings, Nathan T. Connell, Fernando F. Corrales‐Medina, Augusto B. Federici, Veronica H. Flood, Floor Heubel‐Moenen, Jill M. Johnsen, Geoffrey Kuppens, Davide Matino, Carolyn Millar, Ingmar Schoen, Anish Sharda, Robert F. Sidonio Jr, Alok Srivastava, Timea Szanto, Angela C. Weyand, Erik Berntorp   +17 more
wiley   +1 more source

Real‐World Outcomes of Prophylaxis With rIX‐FP in Germany: A Prospective, Non‐Interventional Study in Haemophilia B

Haemophilia, EarlyView.
ABSTRACT Introduction Efficacy and safety of albutrepenonacog alfa (rIX‐FP) in people with haemophilia B (PwHB) has been previously demonstrated in clinical trials. However, real‐world data insights are required. Aim To describe real‐world effectiveness and tolerability of rIX‐FP in PwHB in Germany.
Johannes Oldenburg, Swee Wenning, Susanne Holzhauer, Wolfgang Miesbach, Robert Klamroth, Thomas Linhoff, Patrick Sommerer, Christian Pfrepper, Martin Olivieri, all study investigators   +9 more
wiley   +1 more source

Habitat selection and seasonal movements of young bearded seals (Erignathus barbatus) in the Bering Sea. [PDF]

PLoS One, 2018
Cameron MF, Frost KJ, Ver Hoef JM, Breed GA, Whiting AV, Goodwin J, Boveng PL.   +6 more
europepmc   +1 more source

Optimizing Perioperative Management of Haemophilia B With rFIX‐FP: Pharmacokinetic Validation of the Hemoptidose Tool

Haemophilia, EarlyView.
Abstract Background Surgical management of haemophilia B requires precise factor IX replacement to ensure adequate haemostasis while optimizing factor consumption. Extended half‐life rFIX‐FP simplifies perioperative management but exhibits substantial pharmacokinetic variability.
Xavier Delavenne, Célia Vollard, Nicolas Drillaud, Sabine Castet, Nicolas Luyck, Emilie Hénin, Julien Denis‐Le Seve, Fabienne Volot, Brigitte Tardy, Stéphanie Désage, Benoît Guillet   +10 more
wiley   +1 more source

Responsiveness and Minimal Important Change of the Haemophilia Activities List in Patients With Inherited Bleeding Disorders

Haemophilia, EarlyView.
ABSTRACT Introduction The Haemophilia Activities List (HAL) is a disease‐specific patient‐reported outcome measure (PROM) that is widely used in both healthcare and research in people with inherited bleeding disorders (PWBD), but information on responsiveness and minimal important change (MIC) is lacking.
Johan Blokzijl, Isolde A. R. Kuijlaars, Martijn F. Pisters, Cindy Veenhof, Janjaap van der Net, Roger E. G. Schutgens, Kathelijn Fischer, Merel A. Timmer   +7 more
wiley   +1 more source